B cell receptor triggering sensitizes human B cells to TRAIL-induced apoptosis

Journal of Leukocyte Biology

Volumn 88, Issue 5, 2010, Pages 937-945

  Guerreiro Cacais, Andre Ortlieb ^a,c   Levitskaya, Jelena ^b   Levitsky, Victor ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cell death; Primary B cell

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD40 ANTIGEN; CD5 ANTIGEN; FAS ANTIGEN; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL PROTECTION; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MEMORY CELL; MITOCHONDRION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION;

ANTIBODY SPECIFICITY; ANTIGENS, CD40; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; BCL-X PROTEIN; CELL CULTURE TECHNIQUES; CELL LINE; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC MEMORY; RECEPTORS, ANTIGEN, B-CELL; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649584667     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0510246     Document Type: Article

References (39)

1. LeBlanc, H. N., Ashkenazi, A. (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10, 66-75.
2. Zauli, G., Melloni, E., Capitani, S., Secchiero, P. (2009) Role of full-length osteoprotegerin in tumor cell biology. Cell. Mol. Life Sci. 66, 841-851.
3. Ashkenazi, A., Holland, P., Eckhardt, S. G. (2008) Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 26, 3621-3630.
4. Falschlehner, C., Emmerich, C. H., Gerlach, B., Walczak, H. (2007) TRAIL signaling: decisions between life and death. Int. J. Biochem. Cell Biol. 39, 1462-1475. (Pubitemid 47031030)
5. Schaefer, U., Voloshanenko, O., Willen, D., Walczak, H. (2007) TRAIL: a multifunctional cytokine. Front. Biosci. 12, 3813-3824.
6. Sedger, L. M., Glaccum, M. B., Schuh, J. C., Kanaly, S. T., Williamson, E., Kayagaki, N., Yun, T., Smolak, P., Le, T., Goodwin, R., Gliniak, B. (2002) Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. 32, 2246-2254.
7. Diehl, G. E., Yue, H. H., Hsieh, K., Kuang, A. A., Ho, M., Morici, L. A., Lenz, L. L., Cado, D., Riley, L. W., Winoto, A. (2004) TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21, 877-889.
8. Finnberg, N., Gruber, J. J., Fei, P., Rudolph, D., Bric, A., Kim, S. H., Burns, T. F., Ajuha, H., Page, R., Wu, G. S., Chen, Y., McKenna, W. G., Bernhard, E., Lowe, S., Mak, T., El-Deiry, W. S. (2005) DR5 knockout mice are compromised in radiation-induced apoptosis. Mol. Cell. Biol. 25, 2000-2013.
9. Finnberg, N., Klein-Szanto, A. J., El-Deiry, W. S. (2008) TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J. Clin. Invest. 118, 111-123.
10. Song, K., Chen, Y., Goke, R., Wilmen, A., Seidel, C., Goke, A., Hilliard, B. (2000) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med. 191, 1095-1104.
11. Lamhamedi-Cherradi, S. E., Zheng, S. J., Maguschak, K. A., Peschon, J., Chen, Y. H. (2003) Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat. Immunol. 4, 255-260.
12. Lamhamedi-Cherradi, S. E., Zheng, S., Tisch, R. M., Chen, Y. H. (2003) Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 52, 2274-2278.
13. Mi, Q. S., Ly, D., Lamhamedi-Cherradi, S. E., Salojin, K. V., Zhou, L., Grattan, M., Meagher, C., Zucker, P., Chen, Y. H., Nagle, J., Taub, D., Delovitch, T. L. (2003) Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes 52, 1967-1975.
14. Cretney, E., McQualter, J. L., Kayagaki, N., Yagita, H., Bernard, C. C., Grewal, I. S., Ashkenazi, A., Smyth, M. J. (2005) TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunol. Cell Biol. 83, 511-519. (Pubitemid 41805753)
15. Hilliard, B., Wilmen, A., Seidel, C., Liu, T. S., Goke, R., Chen, Y. (2001) Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J. Immunol. 166, 1314-1319.
16. Ursini-Siegel, J., Zhang, W., Altmeyer, A., Hatada, E. N., Do, R. K., Yagita, H., Chen-Kiang, S. (2002) TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J. Immunol. 169, 5505-5513.
17. Kayagaki, N., Yamaguchi, N., Abe, M., Hirose, S., Shirai, T., Okumura, K., Yagita, H. (2002) Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL). Cell. Immunol. 219, 82-91.
18. Travert, M., Ame-Thomas, P., Pangault, C., Morizot, A., Micheau, O., Semana, G., Lamy, T., Fest, T., Tarte, K., Guillaudeux, T. (2008) CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-κB activation and up-regulation of c-FLIP and Bcl-xL. J. Immunol. 181, 1001-1011.
19. Snow, A. L., Vaysberg, M., Krams, S. M., Martinez, O. M. (2006) EBV B lymphoma cell lines from patients with post-transplant lymphoproliferative disease are resistant to TRAIL-induced apoptosis. Am. J. Transplant. 6, 976-985.
20. Guerreiro-Cacais, A. O., Uzunel, M., Levitskaya, J., Levitsky, V. (2007) Inhibition of heavy chain and β2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein- Barr virus replication. J. Virol. 81, 1390-1400.
21. Hao, Z., Duncan, G. S., Seagal, J., Su, Y. W., Hong, C., Haight, J., Chen, N. J., Elia, A., Wakeham, A., Li, W. Y., Liepa, J., Wood, G. A., Casola, S., Rajewsky, K., Mak, T. W. (2008) Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis. Immunity 29, 615-627.
22. Mouhamad, S., Besnault, L., Auffredou, M. T., Leprince, C., Bourgeade, M. F., Leca, G., Vazquez, A. (2004) B cell receptor-mediated apoptosis of human lymphocytes is associated with a new regulatory pathway of Bim isoform expression. J. Immunol. 172, 2084-2091.
23. Garrone, P., Neidhardt, E. M., Garcia, E., Galibert, L., van Kooten, C., Banchereau, J. (1995) Fas ligation induced apoptosis of CD40-activated human B lymphocytes. J. Exp. Med. 182, 1265-1273.
24. Enders, A., Bouillet, P., Puthalakath, H., Xu, Y., Tarlinton, D. M., Strasser, A. (2003) Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J. Exp. Med. 198, 1119-1126.
25. Schneider, T. J., Grillot, D., Foote, L. C., Nunez, G. E., Rothstein, T. L. (1997) Bcl-x protects primary B cells against Fas-mediated apoptosis. J. Immunol. 159, 4834-4839.
26. Wang, J., Lobito, A. A., Shen, F., Hornung, F., Winoto, A., Lenardo, M. J. (2000) Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. Eur. J. Immunol. 30, 155-163.
27. Mizuno, T., Zhong, X., Rothstein, T. L. (2003) Fas-induced apoptosis in B cells. Apoptosis 8, 451-460.
28. Mouhamad, S., Besnault, L., Auffredou, M. T., Leprince, C., Bourgeade, M. F., Leca, G., Vazquez, A. (2004) B cell receptor-mediated apoptosis of human lymphocytes is associated with a new regulatory pathway of Bim isoform expression. J. Immunol. 172, 2084-2091.
29. Degterev, A., Lugovskoy, A., Cardone, M., Mulley, B., Wagner, G., Mitchison, T., Yuan, J. (2001) Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat. Cell Biol. 3, 173-182.
30. Berland, R., Wortis, H. H. (2002) Origins and functions of B-1 cells with notes on the role of CD5. Annu. Rev. Immunol. 20, 253-300.
31. Zerafa, N., Westwood, J. A., Cretney, E., Mitchell, S., Waring, P., Iezzi, M., Smyth, M. J. (2005) Cutting edge: TRAIL deficiency accelerates hematological malignancies. J. Immunol. 175, 5586-5590.
32. Henson, E. S., Johnston, J. B., Gibson, S. B. (2008) The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk. Lymphoma 49, 27-35.
33. Secchiero, P., Vaccarezza, M., Gonelli, A., Zauli, G. (2004) TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. Curr. Pharm. Des. 10, 3673-3681.
34. Tabrizi, S. J., Niiro, H., Masui, M., Yoshimoto, G., Iino, T., Kikushige, Y., Wakasaki, T., Baba, E., Shimoda, S., Miyamoto, T., Hara, T., Akashi, K. (2009) T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins. J. Immunol. 182, 1490-1499.
35. Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S., Green, D. R., Schoenberger, S. P. (2005) CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434, 88-93.
36. Hamilton, S. E., Wolkers, M. C., Schoenberger, S. P., Jameson, S. C. (2006) The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. Nat. Immunol. 7, 475-481.
37. Sedger, L. M., Katewa, A., Pettersen, A. K., Osvath, S. R., Farrell, G. C., Stewart, G. J., Bendall, L. J., Alexander, S. I. (2010) Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL and TRAIL double-deficient mice. Blood 115, 3258-3268.
38. Sedger, L. M., Glaccum, M. B., Schuh, J. C., Kanaly, S. T., Williamson, E., Kayagaki, N., Yun, T., Smolak, P., Le, T., Goodwin, R., Gliniak, B. (2002) Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. 32, 2246-2254.
39. Breitfeld, D., Ohl, L., Kremmer, E., Ellwart, J., Sallusto, F., Lipp, M., Forster, R. (2000) Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J. Exp. Med. 192, 1545-1552.